-
公开(公告)号：US09352013B2
公开(公告)日：2016-05-31
申请号：US14313258
申请日：2014-06-24
发明人： Carl Spana , Robert Jordan , Jeffrey D. Edelson
IPC分类号： A61K38/12 , C07K7/64 , A61P15/00 , A61K38/34 , A61K31/4178
CPC分类号： A61K38/12 , A61K31/4178 , A61K38/34
摘要： Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
摘要翻译： 使用约1.0mg至1.75mg之间的皮肤投与剂量的布鲁米诺苷或其药学上可接受的米曲米知识的盐来治疗女性的女性性功能障碍，同时减少或最小化不希望的副作用。
-
公开(公告)号：US20220362328A1
公开(公告)日：2022-11-17
申请号：US17864486
申请日：2022-07-14
发明人： Carl Spana , Robert Jordan , Jeffrey D. Edelson
IPC分类号： A61K38/12 , A61K38/34 , A61K31/4178
摘要： Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
-
公开(公告)号：US20130274207A9
公开(公告)日：2013-10-17
申请号：US13653508
申请日：2012-10-17
CPC分类号： A61K38/12 , A61B17/3468 , A61B17/3478 , A61B18/082 , A61B18/1477 , A61B18/1492 , A61B2017/00247 , A61B2018/00404 , A61B2018/00577 , A61B2018/1495 , A61K38/2242 , A61M25/0069 , A61M25/065 , A61M2025/0042 , A61N1/0587 , A61N5/1027 , A61N2001/0585 , A61N2005/0612 , A61N2005/063 , C07K14/582
摘要： Use of constructs which bind to one or more natriuretic peptide receptors and include a plurality of amino acid residues and at least one amino acid surrogate of formula I: where R, R′, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, for the prophylaxis or treatment of airway diseases, including but not limited to inflammation-related airway diseases, acute asthma or COPD, methods of prophylaxis and treatment of airway diseases and pharmaceutical compositions and formulations for the prophylaxis or treatment of airway diseases.
摘要翻译： 使用结合一种或多种利尿钠肽受体并包括多个氨基酸残基和至少一个式I的氨基酸替代物的构建体：其中R，R'，Q，Y，W，Z，J，x和n 包括但不限于炎症相关的气道疾病，急性哮喘或COPD，预防和治疗气道疾病的方法以及药物的方法，如说明书中所定义的，以及任选的至少一个假体组，用于预防或治疗气道疾病 用于预防或治疗气道疾病的组合物和制剂。
-
公开(公告)号：US20190216888A1
公开(公告)日：2019-07-18
申请号：US16368417
申请日：2019-03-28
发明人： Carl Spana , Robert Jordan , Jeffrey D. Edelson
IPC分类号： A61K38/12 , A61K38/34 , A61K31/4178
CPC分类号： A61K38/12 , A61K31/4178 , A61K38/34
摘要： Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
-
公开(公告)号：US10286034B2
公开(公告)日：2019-05-14
申请号：US15642772
申请日：2017-07-06
发明人： Carl Spana , Robert Jordan , Jeffrey D. Edelson
IPC分类号： A61K38/12 , A61K38/34 , A61P15/00 , A61K31/4178
摘要： Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
-
公开(公告)号：US20180085425A1
公开(公告)日：2018-03-29
申请号：US15642772
申请日：2017-07-06
发明人： Carl Spana , Robert Jordan , Jeffrey D. Edelson
IPC分类号： A61K38/12
CPC分类号： A61K38/12 , A61K31/4178 , A61K38/34
摘要： Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
-
公开(公告)号：US09700592B2
公开(公告)日：2017-07-11
申请号：US14704223
申请日：2015-05-05
发明人： Carl Spana , Robert Jordan , Jeffrey D. Edelson
CPC分类号： A61K38/12 , A61K31/4178 , A61K38/34
摘要： Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
-
8.发明申请公开(公告)号：US20140378392A1
公开(公告)日：2014-12-25
申请号：US14313258
申请日：2014-06-24
发明人： Carl Spana , Robert Jordan , Jeffrey D. Edelson
IPC分类号： A61K38/12
CPC分类号： A61K38/12 , A61K31/4178 , A61K38/34
摘要： Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
摘要翻译： 使用约1.0mg至1.75mg之间的皮肤投与剂量的布鲁米诺苷或其药学上可接受的米曲米知识的盐用于治疗女性的女性性功能障碍，同时减少或最小化不良副作用。
-
公开(公告)号：US20210060120A1
公开(公告)日：2021-03-04
申请号：US17081732
申请日：2020-10-27
发明人： Carl Spana , Robert Jordan , Jeffrey D. Edelson
IPC分类号： A61K38/12 , A61K38/34 , A61K31/4178
摘要： Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
-
10.发明申请公开(公告)号：US20150231196A1
公开(公告)日：2015-08-20
申请号：US14704223
申请日：2015-05-05
发明人： Carl Spana , Robert Jordan , Jeffrey D. Edelson
IPC分类号： A61K38/12
CPC分类号： A61K38/12 , A61K31/4178 , A61K38/34
摘要： Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
摘要翻译： 使用约1.0mg至1.75mg之间的皮肤投与剂量的布鲁米诺苷或其药学上可接受的米曲米知识的盐来治疗女性的女性性功能障碍，同时减少或最小化不希望的副作用。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.042 秒)
